Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MARX Biotech CoROCO:7731 -3.18%10 Quick Ratio is 1.42 as of Dec. 2025, which is 30% below its 10-year median of 2.03. GuruFocus rates ROCO:7731 with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 683 Healthcare Providers & Services companies, MARX Biotech Co ranks better than 54.61% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. MARX Biotech Co's quick ratio for the quarter that ended in Dec. 2025 was 1.42.
MARX Biotech Co has a quick ratio of 1.42. It generally indicates good short-term financial strength.
The historical rank and industry rank for MARX Biotech Co's Quick Ratio or its related term are showing as below:
ROCO:7731'
s Quick Ratio Range Over the Past 10 Years
Min: 0.79 Med: 2.03 Max: 3.23
Current: 1.42
During the past 6 years, MARX Biotech Co's highest Quick Ratio was 3.23. The lowest was 0.79. And the median was 2.03.
ROCO:7731's Quick Ratio is ranked better than 54.61% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 1.32
vs ROCO:7731: 1.42
MARX Biotech Co (ROCO:7731) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
MARX Biotech Co Quick Ratio Related Terms
MARX Biotech Co Quick Ratio Historical Data
* Premium members only.
The historical data trend for MARX Biotech Co's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, MARX Biotech Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MARX Biotech Co Quick Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MARX Biotech Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where MARX Biotech Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
MARX Biotech Co's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MARX Biotech Co (ROCO:7731) has a Quick Ratio of 1.42 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on MARX Biotech Co and its competitors. This is 30% below median its historical median of 2.03. Over the past decade, MARX Biotech Co's Quick Ratio has ranged from 0.79 to 3.23. According to the industry distribution chart, MARX Biotech Co ranks #310 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 45.4%.
Is MARX Biotech Co's Quick Ratio too high?
MARX Biotech Co's current Quick Ratio of 1.42 is 30% below median its 10-year median of 2.03. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 3.23. The Healthcare Providers & Services industry median Quick Ratio is 1.32. MARX Biotech Co's value of 1.42 is 7.6% above this industry median. Based on the distribution chart, MARX Biotech Co ranks #310 out of 683 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, MARX Biotech Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does MARX Biotech Co's Quick Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, MARX Biotech Co ranks #310 out of 683 companies for Quick Ratio. This puts MARX Biotech Co in the upper half of its industry. The industry median Quick Ratio is 1.32. MARX Biotech Co's value of 1.42 is 7.6% above this benchmark. Historically, MARX Biotech Co's own Quick Ratio has ranged from 0.79 to 3.23 over the past decade. While the company's 10-year median is 2.03 vs. the industry median of 1.32, MARX Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Healthcare Providers & Services company?
The median Quick Ratio among Healthcare Providers & Services companies is 1.32, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MARX Biotech Co's current Quick Ratio of 1.42 is 7.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on MARX Biotech Co and its competitors. For the Healthcare Providers & Services industry, the median Quick Ratio is 1.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MARX Biotech Co's current Quick Ratio is 1.42, which is 30% below median its own 10-year median of 2.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MARX Biotech Co stock overvalued right now?
MARX Biotech Co (ROCO:7731) has a current Quick Ratio of 1.42. The current Quick Ratio is 1.42, which is 30% below median its 10-year median of 2.03 and 7.6% above the Healthcare Providers & Services industry median of 1.32. MARX Biotech Co's overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For MARX Biotech Co (ROCO:7731), the current Quick Ratio is 1.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MARX Biotech Co Ltd is a retail company which has developed an O2O and OMO full-channel layout in the online Internet platform and cosmeceutical retail market, and has successfully established itself in the market and Build trust and operational growth on the channel side. It has has established more than three thousand large and small cosmeceutical pharmacies in Taiwan, including: Dashu Pharmacy, Dingding Pharmacy, Cosmed, Watsons, Spring Pharmacy, New Gaoqiao Pharmacy, Anlier Pharmacies, etc.
10GF Score
Get the complete analysis for ROCO:7731
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7731 has been successfully added to your 
